51. Role of 5-hydroxytryptamine in the progression of monocrotaline induced pulmonary hypertension in rats
- Author
-
Kazuo Watanabe, Megumi Yasuoka, Naoki Aikawa, Yasuhiro Hosoda, Shingo Hori, Tsuyoshi Tanaka, and Yae Kanai
- Subjects
Blood Platelets ,Male ,medicine.medical_specialty ,Serotonin ,Physiology ,medicine.drug_class ,Hypertension, Pulmonary ,Pulmonary Artery ,Piperidines ,Right ventricular hypertrophy ,Physiology (medical) ,medicine.artery ,Internal medicine ,Culture Techniques ,Blood plasma ,Medicine ,Animals ,Platelet ,Lung ,Monocrotaline ,business.industry ,Platelet Count ,Triazines ,Receptor antagonist ,medicine.disease ,Pulmonary hypertension ,Rats ,Blood pressure ,Anesthesia ,Pulmonary artery ,Cardiology ,Serotonin Antagonists ,Cardiology and Cardiovascular Medicine ,business - Abstract
Objective: The aim was to clarify the role of serotonin (5-hydroxytryptamine, 5-HT) in monocrotaline induced pulmonary hypertension. Methods: Plasma 5-HT levels, pulmonary capillary platelet count, and vascular responsiveness to 5-HT were evaluated in the model. The effects of the selective 5-HT2 receptor antagonist, DV- 7028, on the development of pulmonary hypertension were also investigated. Results: Plasma 5-HT was raised 12 h to 3 d after monocrotaline administration (60 mg·kg−1), coinciding with accumulation of platelets in the pulmonary circulation. Isolated pulmonary arteries showed hyperreactivity to 5-HT at 14 and 21 d after monocrotaline. Administration of DV-7028 (20 mg·kg−1·d−1) attenuated the increase in pulmonary arterial pressure, right ventricular hypertrophy, and medial thickening of the pulmonary arteries. Conclusions: The present study suggests that 5-HT released from platelets contributes to the initiation and progression of monocrotaline induced pulmonary hypertension. Cardiovascular Research 1993; 27 :1619-1623
- Published
- 1993